AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04677972
Drug: Ebselen
RxNorm normalized name: Ebselen
DrugBank: Ebselen (DB12610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione peroxidase mimetic
Trial: NCT02286492
Drug: TAS-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
Trial: NCT04833387
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine:Dose of 1650mg/m2,14days; Radiation:50Gy/25 fractions;IBI308: 200mg on day1 of each cycle, 3 cycles; Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)
Trial: NCT05467462
Drug: I.V carbetocin administration
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: carbetocin was intravenously administered immediately after birth of the baby.
Trial: NCT05467462
Drug: I.V Oxytocin administration
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.
Trial: NCT05467462
Drug: I.V carbetocin and tranexamic acid administration
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.
Trial: NCT05467462
Drug: I.V Oxytocin and tranexamic acid administration
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
Trial: NCT04973891
Drug: Canagliflozin combined with metformin
RxNorm normalized name: canagliflozin / metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.~Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
Trial: NCT04973891
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
Trial: NCT06055491
Drug: Vitamin D3 or Saline injection at ipsilateral deltoid muscle
RxNorm normalized name: vitamin D3
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study group: 1.0mL Vitamin D3 injection control group: 1.0mL saline injection
Trial: NCT05199818
Drug: Palonosetron HCl Buccal Film 0.5 mg
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palonosetron HCl Buccal Film and IV palonosetron placebo, both administered on Day 1
Trial: NCT05199818
Drug: IV Palonosetron 0.25 mg
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Palonosetron and Palonosetron HCl Buccal Film placebo, both administered on Day 1
Trial: NCT04731779
Drug: cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
Trial: NCT05967949
Drug: chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: This subset of patients received chidamide as first-line maintenance therapy.
Trial: NCT06497452
Drug: Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling
Trial: NCT06126354
Drug: Insulin human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
Trial: NCT06126354
Drug: Octreotide Acetate
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
Trial: NCT06126354
Drug: Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
Trial: NCT06126354
Drug: Human Growth Hormone
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
Trial: NCT06126354
Drug: Dexamethasone Oral
RxNorm normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.
Trial: NCT06126354
Drug: 20% D-glucose (aq)
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)
Trial: NCT06138327
Drug: BMN 255
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT01053702
Drug: R475
RxNorm normalized name: Romosozumab
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT06068179
Drug: methimazole, oral, 10mg
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole 15-30mg daily initially then titrate to maintenance dose.
Trial: NCT05130970
Drug: Garadacimab
RxNorm normalized name: Garadacimab
DrugBank: Garadacimab (DB15629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.
Trial: NCT06024213
Drug: indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intervention description: indocyanine green (5 to 10 mg \[ie, 2 to 4 mL of a 2.5 mg/mL solution\]) administered by periareolar or peritumoural route
Trial: NCT06024213
Drug: methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1%), 2-5 mL administered by periareolar or peritumoural route
Trial: NCT06024213
Drug: Technetium (99mTc)
RxNorm normalized name: Technetium (99mTc) HMPAO
DrugBank: Technetium Tc-99m (DB14227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route
Trial: NCT04805710
Drug: clopidogrel combined with rivaroxaban arm
RxNorm normalized name: Rivaroxaban
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients who have been selected will be randomized to the clopidogrel combined with rivaroxaban arm. clopidogrel 75 mg once daily and rivaroxaban 10 mg once daily
Trial: NCT04369560
Drug: Gadobutrol intravesical administration (4mM)
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).
Trial: NCT04369560
Drug: Ferumoxytol intravesical administration (5 mM)
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
Trial: NCT05821309
Drug: PEG 3350
RxNorm normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
Trial: NCT05821309
Drug: Glycerin
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin will be given to patients based on standard of care, at the discretion of the pediatric gastroenterology and pediatric surgery teams. Glycerin administration will not be randomized. For secondary analysis, the microbiomes of those who have and have not received glycerin will be compared.
Trial: NCT05358821
Drug: SAGE-718
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-718 oral softgel lipid capsules
Trial: NCT05378061
Drug: Pituitary adenylate cyclase activating polypeptide-38
RxNorm normalized name: SH-polypeptide-42
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 10 pmol/kg/min PACAP-38.
Trial: NCT06118411
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Tablets
Trial: NCT05257902
Drug: choline alphoscerate
RxNorm normalized name: Choline alphoscerate
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg bid/day
Trial: NCT05095168
Drug: CAN106
RxNorm normalized name: Immunoglobulin G [27-histidine,57-histidine,253-tyrosine,255- threonine,257-glutamic acid], anti-(human complement C5) (human monoclonal CAN106 hybrid y2-chain CH1-hinge region/y4-chain CH2- CH3 region), disulfide with human monoclonal CAN106 Kappa-chain, dimer
DrugBank: CAN-106 (DB18389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.
Trial: NCT04374279
Drug: Bicalutamide 150 Mg Oral Tablet
RxNorm normalized name: bicalutamide 150 MG Oral Tablet
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg by mouth daily for 7 days
Trial: NCT04576091
Drug: Elimusertib
RxNorm normalized name: Elimusertib
DrugBank: Elimusertib (DB19041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03865836
Drug: AT2221
RxNorm normalized name: AT2221
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04736329
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.
Trial: NCT06364956
Drug: Tislelizumab combined with two predefined dose groups of palbociclib
RxNorm normalized name: Tislelizumab
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tislelizumab, 200mg q3W, combined with two predefined dose groups of palbociclib: 100mg QD and 125mg QD, separately.
Trial: NCT06364956
Drug: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After the exploration of Tislelizumab, 200mg q3W combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of Tislelizumab combined with palbociclib was selected for phase II clinical trial.
Trial: NCT05713578
Drug: apantamide+docetaxel+ADT
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.
Trial: NCT05578482
Drug: Dicloxacillin Oral Capsule
RxNorm normalized name: dicloxacillin Oral Capsule
DrugBank: Dicloxacillin (DB00485)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized to either systemic dicloxacillin \& elocon or placebo \& elocon
Trial: NCT00002109
Drug: Thymopentin
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002109
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002109
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002109
Drug: Zalcitabine
RxNorm normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002109
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05109702
Drug: 0.25% Tanfanercept Ophthalmic Solution
DrugBank: Tanfanercept (DB19142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanfanercept ophthalmic solution.
Trial: NCT05417841
Drug: Insulin Degludec and Insulin Aspart Injection
RxNorm normalized name: insulin aspart, human / insulin degludec
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To evaluate the efficacy and safety of the IDegAsp BID in T2DM
Trial: NCT05417841
Drug: Insulin Aspart Injection
RxNorm normalized name: Insulin Aspart Injection
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM
Trial: NCT06524596
Drug: tartaric acid butorphanol
RxNorm normalized name: Tartaric Acid
DrugBank: Butorphanol (DB00611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The group received 0.02 mg/kg tartaric acid butorphanol intravenously over 5 minutes, 30 minutes before anaesthesia induction
Trial: NCT05317013
Drug: CBD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD
Trial: NCT00030355
Drug: homoharringtonine
RxNorm normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06187311
Drug: Rivaroxaban 20 MG
RxNorm normalized name: rivaroxaban 20 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
Trial: NCT06187311
Drug: Rivaroxaban 15 MG
RxNorm normalized name: rivaroxaban 15 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
Trial: NCT02645734
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.25 mg of bevacizumab is injected
Trial: NCT02645734
Drug: ziv-aflibercept 1.25 mg
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.25 mg of ziv-aflibercept is injected
Trial: NCT02645734
Drug: ziv-aflibercept 2.5mg
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2.5 mg of ziv-aflibercept is injected
Trial: NCT05035095
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a daily dose of oral semaglutide.
Trial: NCT05660213
Drug: Atezolizumab + Bevacizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Trial: NCT05660213
Drug: Camrelizumab+Apatinib
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Trial: NCT05660213
Drug: Sintilimab+Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Trial: NCT05950971
Drug: Amiodarone, diltiazem or esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.
Trial: NCT06205342
Drug: Mesenchymal Stem Cells
RxNorm normalized name: Placental Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow derived MSCs
Trial: NCT05312190
Drug: ZhenQi BuXue KouFuYe
RxNorm normalized name: Buxus Chinensis Oil
DrugBank: Jojoba oil (DB14252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
Trial: NCT05100446
Drug: Amoxicillin - high dose dual therapy
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eradication with Amoxicillin 1000mg + 500 mg + 1000mg + 500mg, for 15 days.
Trial: NCT05100446
Drug: Pylera
RxNorm normalized name: Pylera
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eradication with Pylera, for 10 days.
Trial: NCT05100446
Drug: Esomeprazole 40mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40mg, twice a day.
Trial: NCT06180707
Drug: pregabalin gel
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10% pregabalin gel (carbopol-based gel to which the drug has been added) for topical application to teeth before bleaching with hydrogen peroxide
Trial: NCT05312190
Drug: Progesterone Capsules
RxNorm normalized name: Progesterone Capsules
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
Trial: NCT06180707
Drug: gel with 5% potassium nitrate and 2% sodium fluoride
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
Trial: NCT06439303
Drug: Cytisine 1,5 mg
DrugBank: Cytisine (DB09028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious
Trial: NCT05261009
Drug: Peri-capsular Nerve Group (PENG)
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PENG block for postoperative pain management
Trial: NCT05504577
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
Trial: NCT05445882
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa (1,200 mg) will be given via IV infusion every 2 weeks for up to 3 years.
Trial: NCT05445882
Drug: N-803
RxNorm normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.
Trial: NCT06532253
Drug: NVDX3
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)